共 50 条
- [1] Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-AnalysisJOURNAL OF IMMUNOTHERAPY, 2020, 43 (01) : 1 - 7Petrelli, FaustoGrizzi, GiuliaGhidini, MicheleGhidini, AntonioRatti, MargheritaPanni, StefanoCabiddu, MaryGhilardi, MaraBorgonovo, KarenParati, Maria C.Tomasello, GianlucaBarni, SandroBerruti, AlfredoBrighenti, Matteo
- [2] Frequency of delayed immune-related adverse events (irAEs) in hospitalized patients treated with immune checkpoint inhibitors (ICIs)JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Durbin, SiennaZubiri, LeyrePerlman, KatherineMolina, GabrielJacoby, TedShah, NishiReynolds, Kerry Lynn
- [3] Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)ONCOIMMUNOLOGY, 2023, 12 (01):Daban, A.Gonnin, C.Phan, L.Saldmann, A.Granier, C.Lillo-Lelouet, A.Le Beller, C.Pouchot, J.Weiss, L.Tartour, E.Fabre, E.Medioni, J.Oudard, S.Vano, Y. A.Dragon-Durey, M. A.Simonaggio, A.
- [4] Early incidence of immune-related adverse events (irAEs) predicts efficacy in patients (pts) with solid tumors treated with immune-checkpoint inhibitors (ICIs).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Morehouse, ChrisAbdullah, Shaad EssaGao, ChenDar, Mohammed M.Ranade, KoustubhHiggs, Brandon W.
- [5] Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs).JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Riudavets, MarionaBarba, AndresMaroto, PabloSullivan, Ivana GabrielaAnguera, GeorgiaPaez, Daviddel Carpio, LuisCallejo, AnaGonzalez Blanco, CintiaGarcia Planellas, EstherCastillo, DiegoFacundo, CarmeGenua, IdoiaMartin Lorente, CristinaVirgili, AnaSebio, AnaGallego, OscarLopez-Pousa, AntonioBarnadas, AgustMajem, Margarita
- [6] Association of immune-related adverse (irAEs) with immunecheckpoint inhibitors (ICIs) efficacy in solid tumorsANNALS OF ONCOLOGY, 2018, 29 : 427 - 427Riudavets Melia, M.del Carpio, L. P.Gabriela Sullivan, I.Barba Joaquin, A.Maroto Rey, P.Anguera Palacios, G.Paez Lopez-Bravo, D.Callejo Perez, A.Gonzalez Blanco, C.Castillo Villegas, D.Facundo Molas, C.Garcia Planella, E.Genua Trullos, I.Lopez Pousa, A.Sebio Garcia, A.Martin Lorente, C.Virgili Manrique, A. C.Gallego Rubio, O.Barnadas Molins, A.Majem Tarruella, M.
- [7] Immune checkpoint inhibitors (ICIs) in gastrointestinal (GI) cancer: Immune-related adverse events (IRAEs) and efficacy.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Das, SatyaCiombor, Kristen KeonHaraldsdottir, SigurdisPumpalova, Yoanna S.Sahin, Ibrahim HalilShyr, YuChu, Shih-KaiLin, Emily Pei-YingHsu, Chih-YuanGoff, Laura WilliamsCardin, Dana BacklundBilen, Mehmet AsimBerlin, JordanWu, Christina
- [8] Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR)JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Day, DaphneKhoja, LeilaChen, Tom Wei-WuSiu, Lillian L.Hansen, Aaron Richard
- [9] Immune-related adverse events (IrAEs) in patients receiving immune checkpoint inhibitorsJOURNAL OF TRANSLATIONAL MEDICINE, 2020, 18Ferrarini, AlessiaBenfaremo, DevisRossetti, GiuliaMorgese, FrancescaPomponio, GiovanniBerardi, RossanaGabrielli, Armando
- [10] Endocrine immune-related adverse events (irAEs) of combined immunotherapy in solid tumors: Systematic review and meta-analysisANNALS OF ONCOLOGY, 2021, 32 : S845 - S845Tsoukalas, N. G.Tsitsimpis, A.Katsouda, A.Arvanitou, E.Bagos, P.